Search company, investor...

EVOQ Therapeutics


Convertible Note | Alive

Total Raised


Last Raised

$50K | 4 yrs ago

About EVOQ Therapeutics

EVOQ Therapeutics develops vaccines that produce robust anti-tumor immunity against new tumor epitopes while broadening T-cell responses against multiple tumor epitopes.

Headquarters Location

534 Glendale Circle

Ann Arbor, Michigan, 48103,

United States

Missing: EVOQ Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: EVOQ Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest EVOQ Therapeutics News

BRIEF—EVOQ signs licensing deal with Amgen

Jan 18, 2021

USA-based EVOQ Therapeutics has entered into a license and collaboration agreement with biotech major Amgen for the discovery and development of novel drugs for autoimmune disorders. Under the terms of the accord, Amgen and EVOQ will collaborate on pre-clinical development and Amgen will be responsible for clinical development and commercialization. In exchange for exclusive rights to selected autoimmune programs, Amgen will make upfront and milestone payments potentially totaling more than $240 million, as well as pay royalties on sales of resulting therapies. Amgen is a world leader in the treatment of autoimmune disorders, with a portfolio that includes innovative medicines, including Otezla (apremilast), which it picked up from Celgene after it merged with Bristol Myers Squibb in 2019. It also has Enbrel (etanercept), and biosimilar products, such as Amgevita, a biosimilar to Humira (adalimumab)) and Avsola, a biosimilar to Remicade.

EVOQ Therapeutics Frequently Asked Questions (FAQ)

  • Where is EVOQ Therapeutics's headquarters?

    EVOQ Therapeutics's headquarters is located at 534 Glendale Circle, Ann Arbor.

  • What is EVOQ Therapeutics's latest funding round?

    EVOQ Therapeutics's latest funding round is Convertible Note.

  • How much did EVOQ Therapeutics raise?

    EVOQ Therapeutics raised a total of $50K.

  • Who are the investors of EVOQ Therapeutics?

    Investors of EVOQ Therapeutics include Detroit Innovate and University of Michigan.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.